BradleyC.Graveline

Partner•Co-Leader, Cannabis Industry Team
LINKEDIN
Bradley Graveline

Overview

Brad Graveline is a nationally recognized first-chair trial lawyer with more than 30 years of experience litigating patent infringement cases. He is also co-chair of our Cannabis industry team, advising cannabis and ancillary businesses on their intellectual property and regulatory issues.

Patent litigation

Named on Crain’s Chicago Business’ 2025 list of Notable Litigator & Trial Attorneys, Brad’s patent infringement experience includes technologies such as pharmaceuticals, biologics, medical devices, nutrition supplements, security screening systems, computer software and wireless communications.

On behalf of client SecurityPoint Holdings Inc., Brad led the trial team that secured the largest-ever patent infringement damages award against the U.S. government. In a decision from the United States Court of Federal Claims, the court awarded SecurityPoint more than $170 million based on the government’s unauthorized use of SecurityPoint’s patent covering a method of using carts to manage and move trays at security screening checkpoints at U.S. airports.

Life sciences patent litigation

With substantial experience in life sciences patent litigation, Brad represents drug, medical device and diagnostics manufacturers.

Trademarks

Drawing on extensive experience in trademark law, Brad litigates trademark infringement cases, leads a trademark prosecution and management team responsible for global trademark portfolio protection and enforcement, and advises clients on trademark strategy and procurement. He is also a qualified mediator for the Northern District of Illinois Lanham Act Mediation Program.

Cannabis

Brad leads Sheppard’s Cannabis team, which was ranked nationally by Chambers USA in 2025. He advises clients in the cannabis sector on intellectual property procurement and management, technology transactions and regulatory matters. Brad is the lead author of the book Illinois Marijuana Laws and Regulations (LexisNexis, 2025).

In his free time, Brad enjoys the outdoors, including hiking, skiing, sailing, mountain biking and golf.

Experience

Representative Patent Litigation Matters

  • Currently representing manufacturer of cochlear implants against allegation that the companies’ cochlear implant infringe multiple patents. The Alfred E. Mann Foundation for Scientific Research v. Cochlear Limited and Cochlear Americas (C.D.Cal.)
  • Representation of Alembic Pharmaceuticals in ANDA litigation relating to febuxostat. Teijin, et al. v. Alembic, et al.
  • Representation of Abon and Incepta in ANDA litigation relating to extended release gabapentin. Depomed, Inc. v. Incepta Pharmaceuticals, et al.
  • Representation of Everett Laboratories in multiple cases involving nutritional supplements. Everett Laboratories, Inc. v. Acella Pharmaceuticals, LLC.
  • Representation of Teva in patent infringement litigation relating to the oral contraceptive product YAZ®. Teva Pharmaceuticals USA, Inc., et al. v. Bayer Schering Pharma AG, et al.
  • Representation of Barr in ANDA case involving patents relating to dutasteride, the active ingredient in Avodart®, which is used for the treatment of benign prostatic hyperplasia. SmithKline Beecham Corporation v. Barr Laboratories, Inc.
  • Representation of Barr in ANDA litigation relating to Travatan® and Travatan Z®, which are used for the treatment of intraocular pressure in patients with open-angle glaucoma. Alcon Research, Ltd. v. Barr Laboratories, Inc.
  • Representation of Barr in an ANDA case involving patents relating to raloxifene, the active ingredient in Lilly's Evista product, which is used in the treatment of osteoporosis. Eli Lilly and Company, et al., v. Barr Laboratories, Inc.
  • Representation of Barr Laboratories in ANDA litigation relating to Femcon Fe®, a chewable oral contraceptive product. Warner Chilcott Company, Inc. v. Barr Laboratories, Inc.
  • Representation of Barr Laboratories in ANDA litigation relating to Focalin XR®, a drug product used in the treatment of attention deficit disorders. Celgene Corporation, et al. v. Barr Laboratories, Inc. 
  • Representation of Barr Laboratories in ANDA litigation relating to Entocort EC®, a drug product used in the treatment of inflammatory bowel disease. AstraZeneca LP, et al. v. Barr Laboratories, Inc. 
  • Representation of Barr in an ANDA case relating to Celgene’s Thalomid® drug product. Celgene Corporation v. Barr Laboratories, Inc. 
  • Representation of Sun and Caraco Pharmaceutical Laboratories, Ltd. in ANDA cases relating to Schering’s patent for Clarinex®, a pharmaceutical product used to treat allergy symptoms. Schering Corporation v. Sun Pharmaceutical Industries, Ltd., et al. 
  • Representation of Sun in cases relating to Cardene® I.V., an injectable drug product used for short-term treatment of hypertension. PDL Biopharma, Inc. v. Sun Pharmaceutical Industries, Ltd. 
  • Representation of Abbott Laboratories in a patent infringement case relating to Humira®. Rockefeller Univ. and Chiron Corp. v. Abbott Laboratories 
  • Representation of Barr Laboratories in ANDA litigation relating to the oral contraceptive Mircette®. Bio-Technology General Corp. v. Duramed Pharmaceuticals, Inc. 
  • Representation of Barr Laboratories in ANDA litigation relating to fentanyl, a drug product used for pain relief. Cephalon, Inc., et al. v. Barr Laboratories, Inc. 
  • Representation of Abbott in a patent infringement case relating to Abbott’s patents covering a remote glucose monitoring device. Abbott Diabetes Care, Inc. v. DexCom, Inc.
  • Representation of SecurityPoint Holdings, Inc. in patent infringement litigation relating to security checkpoint systems. SecurityPoint Holdings, Inc. v. U.S.A.
  • Representation of a large national retailer in patent infringement litigation involving Wi-Fi technology.
  • Representation of HTC in patent infringement litigation involving wireless transmission of caller ID information.
Credentials
Education

J.D., Northwestern University, Editor of the Journal of Criminal Law and Criminology, 1990

B.A., DePauw University, 1987

Admissions

Illinois

Northern District of Illinois

District of Colorado

Eastern District of Michigan

Western District of Wisconsin

U.S. Court of Federal Claims

U.S. Supreme Court

U.S. Court of Appeals for the Federal Circuit

U.S. Court of Appeals for the Seventh Circuit

U.S. Court of Appeals for the Ninth Circuit

Honors

Litigation Star, Benchmark Litigation, 2023, 2025-2026

Illinois Super Lawyer, Super Lawyers, 2018-2026

Chicago Notable Litigators and Trial Attorneys, Crain's Chicago Business, 2025

Thought Leadership
  • Speaker, "Examining the Use of Clinical Trials as Prior Art: How to Thread the Needle on Protecting IP and Mandated Disclosures," The Hatch-Waxman Practitioners Think Tank of Paragraph IV Disputes, October 15, 2024
  • Speaker, "International Markets Built and Driven by Canadian Expertise," O'CannaBiz, June 1, 2022
  • Speaker, "Legal Issues Impacting Canadian Cannabis Companies Entering The U.S. Market," Montreal Cannabis Expo., September 21, 2022
  • Panelist, "Trade Secrets and Patents: A Comprehensive Approach to Protecting Intellectual Property," Strafford, January 26, 2022
  • Presenter, Seventh Annual Paragraph IV Master Symposium, American Conference Institute, Chicago, Illinois, October 3-4, 2019
  • "Risky Business: Examining New Guidance for Calculating Damages in the Aftermath of an At-Risk Launch," American Conference Institute, New York, April 25, 2016
  • "Establishing Personal and General Jurisdiction in a Paragraph IV Case in the Aftermath of Daimler and Mylan," American Conference Institute, Chicago, Illinois, September 30, 2015
  • "The Advanced Forum for Brand Name and Generic Counsel on the Intricacies of Extreme Hatch-Waxman Litigation," American Conference Institute, Chicago, Illinois, October 1, 2014
  • "The Drug Approval Process in the U.S.," Sheppard Mullin conference on "Overview of U.S. Drug Application and Patent Litigation Process: What Korean Companies Need to Know to Enter into the U.S. Market," Seoul, Korea, April 9, 2014

Presentations